Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.